Neotope Biosciences Limited Patent applications |
Patent application number | Title | Published |
20150056187 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease. | 02-26-2015 |
20150024433 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease. | 01-22-2015 |
20140348843 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 11-27-2014 |
20140314744 | MCAM ANTAGONISTS AND METHODS OF TREATMENT - Described herein are MCAM antagonists, including MCAM antagonist antibodies capable of inhibiting the interaction between MCAM and it ligand, a laminin α4 chain, e.g., an α4 chain of laminin 411. These MCAM antagonists, e.g., anti-MCAM antibodies, may be useful to treat neuroinflammatory conditions, for example, multiple sclerosis and Parkinson's disease, by inhibiting the infiltration of MCAM-expressing cells into the central nervous system (CNS), e.g., extravasation of TH17 cells into the CNS. | 10-23-2014 |
20140275495 | Humanized Antibodies That Recognize Alpha-Synuclein - The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease. | 09-18-2014 |
20140127225 | COMPOSITIONS AND METHODS FOR TREATING DISEASES OF PROTEIN AGGREGATION INVOLVING IC3B DEPOSITION - The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment. | 05-08-2014 |
20130108546 | Humanized Antibodies That Recognize Alpha-Synuclein | 05-02-2013 |
20120204275 | APOE IMMUNOTHERAPY - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases. | 08-09-2012 |